Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288321 | 1.00 | CHRNA7 (1.00) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL6680053 | 0.99 | CHRNA7 (0.98) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL6287307 | 0.99 | CHRNA7 (0.98) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| Hydrochloric Acid SCHEMBL6287303 | 0.99 | CHRNA7 (0.98) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| SCHEMBL6291512 | 0.94 | CHRNA7 (0.89) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| SCHEMBL6389019 | 0.93 | CHRNA7 (0.87) | CHRNA7NPC1RAB9ATP53HPGD | |
| SCHEMBL6389012 | 0.93 | CHRNA7 (0.87) | CHRNA7NPC1RAB9ATP53HPGD | |
| SCHEMBL6387402 | 0.87 | CHRNA7 (0.77) | CHRNA7NPC1RAB9ATP53HPGD | |
| SCHEMBL6291001 | 0.85 | CHRNA7 (0.74) | CHRNA7NPC1RAB9AMAPK11MAPK14 | |
| SCHEMBL6288170 | 0.85 | CHRNA7 (0.74) | CHRNA7NPC1RAB9AMAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442037-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | claimed |
| WO-2003042210-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| US-6951868-B2 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | CHRNA7 1760/4885NPC1 172/4885RAB9A 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.